BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. Men with harmful BRCA1 or BRCA2 mutations have a higher risk of prostate cancer. A Toronto Women’s College Hospital research study, The Screen Project, provides Canadians access to affordable population-based genetic testing for the BRCA gene mutation. Watch the video here.
Genetic test for BRCA1/2 Read More »
Scientists report progress toward minimizing unnecessary biopsies: They have identified the molecules likely responsible for the scent of prostate cancer, which could be detected by chemically “sniffing” urine. Read the article here.
‘Sniffing’ urine to detect prostate cancer could prevent unnecessary biopsies Read More »
In almost all cases where prostate cancer spreads to other areas of the body, the disease spreads to the bone first. In a new study, researchers reveal the discovery of an enzyme that helps prostate cancer cells to invade bone. Furthermore, certain antidepressant medications may have the potential to block this enzyme. Read the article here.
Could antidepressants stop prostate cancer from spreading? Read More »
High levels of cholesterol in the blood are frequently linked with aggressive prostate cancer, and researchers at Duke Cancer Institute have learned how the cancer cells hijack cholesterol and fuel its growth. Read the article here.
Prostate Cancer Cells Hijack Blood Cholesterol and Fuel Its Growth Read More »
Leading American and British cancer researchers are urging that all men with advanced prostate cancer strongly consider being tested for inherited gene mutations — both to help steer their treatment and to alert family members who themselves might be at increased risk for a range of cancers. Read the article here.
Leading researchers recommend major change in prostate cancer treatment Read More »
Loyola Medicine is the first center in the Midwest to offer the first effective PET/CT scan for prostate cancer patients. The scan can detect the location and extent of cancer that has recurred after initial treatment and spread to other parts of the body. Prostate PET/CT scans can detect cancer earlier than either CT scans alone or MRI scans. Read the article here.
New PET scan can detect prostate cancer earlier than MRIs and CT scans Read More »
Scientists at Cedars-Sinai Medical Center have developed a new way to identify which prostate cancer patients are likely to develop aggressive types of the disease even if their tumors at first appear to be lower risk. Read the article here.
New way to identify patients at risk for aggressive prostate cancer Read More »
January 2017 Awareness Night The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment Dr. Raj Satkunasivam, MD, MS, FRCSC Urologic Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre Assistant Professor, Division of Urology, Department of Surgery, University of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 40:51 minutes
Men with higher selenium levels may be at lower risk of aggressive prostate cancer, according to a new study. Read the article here.
Selenium May Cut Aggressive Prostate Cancer Risk Read More »
Robert K. Nam, MD, from the Sunnybrook Health Sciences Center in Toronto, and colleagues examined the feasibility of prostate MRI as the primary screening test for prostate cancer in a cohort of unselected men from the general population. All participants underwent prostate multiparametric MRI and random or targeted biopsies as well as prostate-specific antigen testing. Initial results showed that prostate MRI was better to predict prostate cancer than PSA. Read the article here.
Prostate Multiparametric MRI Feasible for PCa Screening Read More »